UBS AM’s Immunomedics Inc IMMU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-371,681
Closed -$31.6M 2621
2020
Q3
$31.6M Sell
371,681
-2,656
-0.7% -$134K 0.02% 644
2020
Q2
$13.3M Sell
374,337
-192,600
-34% -$5.63M 0.01% 843
2020
Q1
$7.64M Sell
566,937
-80,831
-12% -$1.36M 0.01% 932
2019
Q4
$13.7M Sell
647,768
-660,537
-50% -$11.7M 0.01% 860
2019
Q3
$17.3M Buy
1,308,305
+21,053
+2% +$309K 0.01% 797
2019
Q2
$17.9M Buy
1,287,252
+189,241
+17% +$2.85M 0.01% 789
2019
Q1
$21.1M Buy
1,098,011
+371,053
+51% +$5.98M 0.02% 730
2018
Q4
$10.4M Buy
726,958
+65,717
+10% +$1.3M 0.01% 861
2018
Q3
$13.8M Sell
661,241
-23,616
-3% -$559K 0.01% 856
2018
Q2
$16.2M Buy
684,857
+606,701
+776% +$12.2M 0.01% 817
2018
Q1
$1.14M Buy
78,156
+13,007
+20% +$213K ﹤0.01% 1732
2017
Q4
$1.05M Buy
65,149
+29,238
+81% +$345K ﹤0.01% 1730
2017
Q3
$502K Buy
35,911
+678
+2% +$6.76K ﹤0.01% 1945
2017
Q2
$311K Sell
35,233
-32,068
-48% -$225K ﹤0.01% 2025
2017
Q1
$435K Buy
67,301
+52,709
+361% +$267K ﹤0.01% 1909
2016
Q4
$54K Sell
14,592
-21,100
-59% -$62.4K ﹤0.01% 2303
2016
Q3
$116K Hold
35,692
﹤0.01% 2558
2016
Q2
$83K Sell
35,692
-10,200
-22% -$34.1K ﹤0.01% 2593
2016
Q1
$115K Hold
45,892
﹤0.01% 2550
2015
Q4
$141K Hold
45,892
﹤0.01% 2616
2015
Q3
$79K Buy
45,892
+10,200
+29% +$26K ﹤0.01% 2633
2015
Q2
$145K Buy
35,692
+2,300
+7% +$9.4K ﹤0.01% 2641
2015
Q1
$128K Buy
33,392
+2,400
+8% +$10.4K ﹤0.01% 2565
2014
Q4
$149K Hold
30,992
﹤0.01% 2527
2014
Q3
$115K Hold
30,992
﹤0.01% 2493
2014
Q2
$113K Hold
30,992
﹤0.01% 2519
2014
Q1
$130K Buy
30,992
+5,900
+24% +$29.3K ﹤0.01% 2520
2013
Q4
$115K Hold
25,092
﹤0.01% 2487
2013
Q3
$155K Hold
25,092
﹤0.01% 2399
2013
Q2
$137K Buy
+25,092
New +$82.4K ﹤0.01% 2351

UBS AM's IMMU Position: Q4 2020 in Review

UBS AM sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 371,681 shares — an estimated $31.6M sold.

UBS AM first reported a position in IMMU in Q2 2013 and held it in 30 quarters. The position peaked at $31.6M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.

  • UBS AM reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
  • UBS AM sold 371,681 Immunomedics Inc shares in Q4 2020, an estimated $31.6M.
  • UBS AM first reported a position in Immunomedics Inc in Q2 2013 and held it in 30 quarters.
  • UBS AM's Immunomedics Inc position peaked at $31.6M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.

Based on UBS AM's 13F filing for Q4 2020, filed 17 Feb 2021.